Literature DB >> 20067857

Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression.

Leisa A Glantz1, John H Gilmore, David H Overstreet, Kayvon Salimi, Jeffrey A Lieberman, L Fredrik Jarskog.   

Abstract

Although the etiology of schizophrenia remains unknown, diverse neuropathological evidence suggests a disorder of synaptic connectivity. Apoptosis is a form of cell death that helps determine synaptic circuitry during neurodevelopment and altered regulation of apoptosis has been implicated in schizophrenia. Prostate apoptosis response-4 (Par-4) is an upstream regulator of apoptosis preferentially localized to synapses. Brain Par-4 levels are upregulated in response to pro-apoptotic stimuli in rodent models and in patients with classic neurodegenerative diseases. Recently, Par-4 was also found to form a complex with the dopamine D2 receptor (D2DR) in competition with the calcium-binding protein calmodulin, implicating Par-4 as an important regulatory component in normal dopamine signaling. Interestingly, mutant mice with disrupted Par-4/D2DR interaction demonstrated depressive-like behaviors, suggesting a potential role for Par-4 in both depression and schizophrenia. In this study, Par-4, D2DR and calmodulin protein levels were measured using semiquantitative Western blotting in postmortem temporal cortex in subjects with schizophrenia, major depression and bipolar disorder. Compared to normal controls, mean Par-4 levels appeared slightly lower in schizophrenia and bipolar disorder. However, in major depression, Par-4 was decreased by 67% compared to normal controls. No differences were found between any groups for calmodulin or for the D2DR 48 kDa band. The D2DR 98 kDa band was lower by 50% in the schizophrenia compared to control groups. Changes in the Par-4/D2DR signaling pathway represent a novel mechanism that may link apoptotic and dopamine signaling pathways in major depression and schizophrenia. Copyright (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20067857      PMCID: PMC2856798          DOI: 10.1016/j.schres.2009.12.027

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  53 in total

1.  Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia.

Authors:  L A Glantz; D A Lewis
Journal:  Arch Gen Psychiatry       Date:  2000-01

2.  Meta-analysis of regional brain volumes in schizophrenia.

Authors:  I C Wright; S Rabe-Hesketh; P W Woodruff; A S David; R M Murray; E T Bullmore
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

3.  Serial analysis of gene expression in the frontal cortex of patients with bipolar disorder.

Authors:  Y Sun; L Zhang; N L Johnston; E F Torrey; R H Yolken
Journal:  Br J Psychiatry Suppl       Date:  2001-06

4.  The stanley foundation brain collection and neuropathology consortium.

Authors:  E F Torrey; M Webster; M Knable; N Johnston; R H Yolken
Journal:  Schizophr Res       Date:  2000-08-03       Impact factor: 4.939

5.  Par-4 is a synaptic protein that regulates neurite outgrowth by altering calcium homeostasis and transcription factor AP-1 activation.

Authors:  Q Guo; J Xie; X Chang; X Zhang; H Du
Journal:  Brain Res       Date:  2001-06-08       Impact factor: 3.252

6.  Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia.

Authors:  J N Pierri; C L Volk; S Auh; A Sampson; D A Lewis
Journal:  Arch Gen Psychiatry       Date:  2001-05

7.  Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia.

Authors:  L F Jarskog; J H Gilmore; E S Selinger; J A Lieberman
Journal:  Biol Psychiatry       Date:  2000-10-01       Impact factor: 13.382

8.  Association of missense variants of the PRKC, apoptosis, WT1, regulator (PAWR) gene with schizophrenia.

Authors:  Ling-Hsuan Wang; Jen-Yeu Chen; Ying-Jay Liou; Ying-Chieh Wang; I-Ching Lai; Ding-Lieh Liao; Chia-Hsiang Chen
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-01-11       Impact factor: 5.067

9.  Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia.

Authors:  Shirly Amar; Galit Shaltiel; Liad Mann; Alon Shamir; Brian Dean; Elizabeth Scarr; Yuly Bersudsky; R H Belmaker; Galila Agam
Journal:  Int J Neuropsychopharmacol       Date:  2007-08-06       Impact factor: 5.176

10.  No association between prostate apoptosis response 4 gene (PAWR) in schizophrenia and mood disorders in a Japanese population.

Authors:  Taro Kishi; Masashi Ikeda; Tsuyoshi Kitajima; Tatsuyo Suzuki; Yoshio Yamanouchi; Yoko Kinoshita; Kunihiro Kawashima; Norio Ozaki; Nakao Iwata
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-06-05       Impact factor: 3.568

View more
  13 in total

Review 1.  Novel dopamine D2 receptor signaling through proteins interacting with the third cytoplasmic loop.

Authors:  Kohji Fukunaga; Norifumi Shioda
Journal:  Mol Neurobiol       Date:  2011-12-20       Impact factor: 5.590

2.  A noncanonical postsynaptic transport route for a GPCR belonging to the serotonin receptor family.

Authors:  Thomas Liebmann; Markus Kruusmägi; Nermin Sourial-Bassillious; Alexander Bondar; Per Svenningsson; Marc Flajolet; Paul Greengard; Lena Scott; Hjalmar Brismar; Anita Aperia
Journal:  J Neurosci       Date:  2012-12-12       Impact factor: 6.167

Review 3.  Allopregnanolone as a mediator of affective switching in reproductive mood disorders.

Authors:  Crystal Edler Schiller; Peter J Schmidt; David R Rubinow
Journal:  Psychopharmacology (Berl)       Date:  2014-05-21       Impact factor: 4.530

4.  Increased density of prohibitin-immunoreactive oligodendrocytes in the dorsolateral prefrontal white matter of subjects with schizophrenia suggests extraneuronal roles for the protein in the disease.

Authors:  Hans-Gert Bernstein; Karl-Heinz Smalla; Diana Dürrschmidt; Gerburg Keilhoff; Henrik Dobrowolny; Johann Steiner; Andrea Schmitt; Michael R Kreutz; Bernhard Bogerts
Journal:  Neuromolecular Med       Date:  2012-06-19       Impact factor: 3.843

5.  Valproate alters dopamine signaling in association with induction of Par-4 protein expression.

Authors:  Saebom Lee; Jaehoon Jeong; Young-Un Park; Yongdo Kwak; Seol Ae Lee; Haeryun Lee; Hyeon Son; Sang Ki Park
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

Review 6.  The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain.

Authors:  Jiyao Sheng; Shui Liu; Yicun Wang; Ranji Cui; Xuewen Zhang
Journal:  Neural Plast       Date:  2017-06-19       Impact factor: 3.599

Review 7.  Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There Implications for Depression?

Authors:  Shenghua Zong; Carolin Hoffmann; Marina Mané-Damas; Peter Molenaar; Mario Losen; Pilar Martinez-Martinez
Journal:  Front Immunol       Date:  2017-07-05       Impact factor: 7.561

Review 8.  The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment.

Authors:  A H Ashok; T R Marques; S Jauhar; M M Nour; G M Goodwin; A H Young; O D Howes
Journal:  Mol Psychiatry       Date:  2017-03-14       Impact factor: 15.992

9.  Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures.

Authors:  Emanuele Felice Osimo; Katherine Beck; Tiago Reis Marques; Oliver D Howes
Journal:  Mol Psychiatry       Date:  2018-03-06       Impact factor: 15.992

10.  Characteristics of gray matter alterations in never-treated and treated chronic schizophrenia patients.

Authors:  Nian Liu; Yuan Xiao; Wenjing Zhang; Biqiu Tang; Jiaxin Zeng; Na Hu; Shah Chandan; Qiyong Gong; Su Lui
Journal:  Transl Psychiatry       Date:  2020-05-12       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.